SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk - Scorecard - MDSpire
Advertisement
SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk
A Korean cohort study found fewer kidney cancer cases among patients with type 2 diabetes who initiated sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors.
Clinical Scorecard: SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk
At a Glance
Category
Detail
Condition
Key Mechanisms
Effects on glucose uptake in renal tumor cells, ketogenesis, autophagy, and glomerular hyperfiltration (not directly tested in this study).
Target Population
Care Setting
Key Highlights
SGLT2 inhibitors associated with a 40% lower hazard of kidney cancer compared to DPP-4 inhibitors, but findings are observational and require further validation.
Guideline-Based Recommendations
Diagnosis
Management
Consider SGLT2 inhibitors for type 2 diabetes management, noting potential association with lower kidney cancer risk, but further validation is needed.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Korean patients aged 20 to 79 years with type 2 diabetes.
SGLT2 inhibitors include dapagliflozin, empagliflozin, ertugliflozin, or ipragliflozin.
Clinical Best Practices
Use propensity score matching to compare treatment effects.
Consider the implications of prescribing patterns and glycemic control in observational studies.
Acknowledge limitations related to follow-up duration and potential undetected cancers.
Consider individual patient factors when prescribing.
